Loading…
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2B | $304M | $210M | $-94M | -212.1% | 4.3% | 2900.0% |
| 2024 | $1.2B | $89M | $7M | $5M | -2.1% | 8.7% | -105.6% |
| 2023 | $1.1B | $-95M | $-126M | $-353M | 65.6% | 21.3% | 186.4% |
| 2022 | $901M | $-46M | $-44M | $-9M | -86.3% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 901 | 1,093 | 1,188 | 1,239 |
| Cost Of Revenue | - | 151 | 174 | 231 | 246 |
| Gross Profit | - | 750 | 919 | 957 | 993 |
| Operating Expense | - | 535 | 672 | 723 | 728 |
| Operating Income | - | 215 | 247 | 234 | 265 |
| EBITDA | - | -46 | -95 | 89 | 304 |
| EBIT | - | -62 | -110 | 61 | 284 |
| Pretax Income | - | -89 | -145 | 20 | 239 |
| Tax Provision | - | -44 | -19 | 13 | 29 |
| Net Income | - | -44 | -126 | 7 | 210 |
| Net Income Common Stockholders | - | -44 | -126 | 7 | 210 |
| Total Expenses | - | 686 | 846 | 954 | 974 |
| Interest Expense | - | 27 | 35 | 41 | 45 |
| Interest Income | - | 19 | 43 | 23 | 22 |
| Research And Development | - | 74 | 116 | 107 | 97 |
| Selling General And Administration | - | 469 | 565 | 612 | 634 |
| Normalized EBITDA | - | 250 | 306 | 285 | 307 |
| Normalized Income | - | 189.84 | 222.46 | 161.84 | 212.63 |
| Market Cap | 4,051.47 | 4,051.47 | 4,051.47 | 4,051.47 | 4,051.47 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Indivior Pharmaceuticals, Inc.this co. | INDV | $4.2B | 19.29↓ discount | -40.92 | -212.1% | 13.84 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.1B | 233.78 | 14.14 | 6.0% | 74.89 |
| Corcept Therapeutics Incorporated | CORT | $4.8B | 49.62 | 7.63 | 15.4% | 103.46 |
| Waystar Holding Corp. | WAY | $4.5B | 43.50 | 1.26 | 2.9% | 16.17 |
| Merit Medical Systems, Inc. |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| MMSI |
| $4.1B |
| 31.84 |
| 2.58 |
| 8.1% |
| 13.45 |
| Amneal Pharmaceuticals, Inc. | AMRX | $3.9B | 55.43 | -56.42 | -101.8% | 10.60 |
| TransMedics Group, Inc. | TMDX | $3.8B | 20.14 | 8.10 | 40.2% | 26.01 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B | 9.58 | 3.05 | 31.9% | 31.04 |
| Catalyst Pharmaceuticals, Inc. | CPRX | $3.4B | 15.60 | 3.50 | 22.5% | 8.92 |
| Peer Median | - | 37.67 | 3.28 | 11.7% | 21.09 | |